These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36395746)

  • 1. An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon.
    Ateudjieu J; Sack DA; Nafack SS; Xiao S; Tchio-Nighie KH; Tchokomeni H; Bita'a LB; Nyibio PN; Guenou E; Mondung KM; Dieumo FFK; Ngome RM; Murt KN; Ram M; Ali M; Debes AK
    Am J Trop Med Hyg; 2022 Nov; 107(5):974-983. PubMed ID: 36395746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia.
    Mwaba J; Chisenga CC; Xiao S; Ng'ombe H; Banda E; Shea P; Mabula-Bwalya C; Mwila-Kazimbaya K; Laban NM; Alabi P; Chirwa-Chobe M; Simuyandi M; Harris J; Iyer AS; Bosomprah S; Scalzo P; Murt KN; Ram M; Kwenda G; Ali M; Sack DA; Chilengi R; Debes AK
    Vaccine; 2021 Jul; 39(32):4516-4523. PubMed ID: 34217572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
    Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
    PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
    Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
    Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
    Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
    Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
    Sow SO; Tapia MD; Chen WH; Haidara FC; Kotloff KL; Pasetti MF; Blackwelder WC; Traoré A; Tamboura B; Doumbia M; Diallo F; Coulibaly F; Onwuchekwa U; Kodio M; Tennant SM; Reymann M; Lam DF; Gurwith M; Lock M; Yonker T; Smith J; Simon JK; Levine MM
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.
    Kanungo S; Desai SN; Saha J; Nandy RK; Sinha A; Kim DR; Bannerjee B; Manna B; Yang JS; Ali M; Sur D; Wierzba TF
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003809. PubMed ID: 26023778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.
    Chowdhury F; Ali Syed K; Akter A; Rahman Bhuiyan T; Tauheed I; Khaton F; Biswas R; Ferdous J; Al Banna H; Ross AG; Mc Millan N; Sharma T; Kanchan V; Pal Singh A; Gill D; Lebens M; Nordqvist S; Holmgren J; Clemens JD; Qadri F
    Vaccine; 2021 Jul; 39(32):4450-4457. PubMed ID: 34218960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
    Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
    Chowdhury F; Akter A; Bhuiyan TR; Tauheed I; Teshome S; Sil A; Park JY; Chon Y; Ferdous J; Basher SR; Ahmed F; Karim M; Ahasan MM; Mia MR; Masud MMI; Khan AW; Billah M; Nahar Z; Khan I; Ross AG; Kim DR; Ashik MMR; Digilio L; Lynch J; Excler JL; Clemens JD; Qadri F
    Vaccine; 2022 Jan; 40(4):640-649. PubMed ID: 34969541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.
    Shah S; Nandy RK; Sethi SS; Chavan B; Pathak S; Dutta S; Rai S; Singh C; Chayal V; Patel C; Kumar NR; Chavan AT; Chawla A; Singh A; Roy AK; Singh N; Baik YO; Lee Y; Park Y; Jeong KH; Ahmed S
    Lancet Reg Health Southeast Asia; 2023 Dec; 19():100256. PubMed ID: 38076719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
    Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
    PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.
    Lopez AL; Deen J; Azman AS; Luquero FJ; Kanungo S; Dutta S; von Seidlein L; Sack DA
    Clin Infect Dis; 2018 Jun; 66(12):1960-1971. PubMed ID: 29177437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
    Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
    Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.
    Baik YO; Choi SK; Kim JW; Yang JS; Kim IY; Kim CW; Hong JH
    J Korean Med Sci; 2014 Apr; 29(4):494-501. PubMed ID: 24753695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
    Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
    Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.
    Kanungo S; Desai SN; Nandy RK; Bhattacharya MK; Kim DR; Sinha A; Mahapatra T; Yang JS; Lopez AL; Manna B; Bannerjee B; Ali M; Dhingra MS; Chandra AM; Clemens JD; Sur D; Wierzba TF
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003574. PubMed ID: 25764513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.